MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 1:40 p.m.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough modifier gene therapy platform as well as its novel biologic product candidate.
He will highlight Ocugen’s lead product candidate, OCU400, which has the potential to treat many forms of retinitis pigmentosa and just received its fourth FDA orphan drug designation. Dr. Musunuri will share Ocugen’s recent accomplishments and its upcoming planned near and medium-term milestones.
Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Format: Company Presentation
Date: Monday, September 21, 2020
Time: 1:40 PM (Eastern Time)
Webcast Link: https://wsw.com/webcast/oppenheimer5/ocgn/2698839
The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place virtually on September 21-23.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.